IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma.

Autor: Sun J; Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.; Department of Biomedical Engineering, Washington University in St. Louis McKelvey School of Engineering, St. Louis, MO, USA., Corradini S; Charles Oakley Laboratories, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, UK., Azab F; Department of Biomedical Engineering, University of Texas Southwestern Medical Center, Dallas, TX, USA., Shokeen M; Department of Biomedical Engineering, Washington University in St. Louis McKelvey School of Engineering, St. Louis, MO, USA.; Department of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.; Alvin J. Siteman Cancer Center, Washington University School of Medicine and Barnes-Jewish Hospital, St. Louis, MO, USA., Muz B; Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Miari KE; Charles Oakley Laboratories, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, UK., Maksimos M; Department of Biomedical Engineering, University of Texas Southwestern Medical Center, Dallas, TX, USA., Diedrich C; Department of Biomedical Engineering, University of Texas Southwestern Medical Center, Dallas, TX, USA., Asare O; Department of Biomedical Engineering, University of Texas Southwestern Medical Center, Dallas, TX, USA., Alhallak K; Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.; Department of Biomedical Engineering, Washington University in St. Louis McKelvey School of Engineering, St. Louis, MO, USA., Park C; Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Lubben B; Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Chen Y; Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Adebayo O; Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Bash H; Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Kelley S; Department of Medicine, Oncology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Fiala M; Department of Medicine, Oncology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Bender DE; Alvin J. Siteman Cancer Center, Washington University School of Medicine and Barnes-Jewish Hospital, St. Louis, MO, USA., Zhou H; Department of Internal Medicine University of Michigan, Ann Arbor, Michigan, USA., Wang S; Department of Internal Medicine University of Michigan, Ann Arbor, Michigan, USA.; Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.; Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan, USA., Vij R; Alvin J. Siteman Cancer Center, Washington University School of Medicine and Barnes-Jewish Hospital, St. Louis, MO, USA.; Department of Medicine, Oncology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Williams MTS; Charles Oakley Laboratories, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, UK., Azab AK; Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, St. Louis, MO, USA. abdelkareem.azab@utsouthwestern.edu.; Department of Biomedical Engineering, Washington University in St. Louis McKelvey School of Engineering, St. Louis, MO, USA. abdelkareem.azab@utsouthwestern.edu.; Department of Biomedical Engineering, University of Texas Southwestern Medical Center, Dallas, TX, USA. abdelkareem.azab@utsouthwestern.edu.; Alvin J. Siteman Cancer Center, Washington University School of Medicine and Barnes-Jewish Hospital, St. Louis, MO, USA. abdelkareem.azab@utsouthwestern.edu.; Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. abdelkareem.azab@utsouthwestern.edu.

Publikováno v: Leukemia [Leukemia] 2024 Nov; Vol. 38 (11), pp. 2355-2365. Date of Electronic Publication: 2024 Aug 30.

Macrophages in Acute Myeloid Leukaemia: Significant Players in Therapy Resistance and Patient Outcomes.

Autor: Miari KE; Charles Oakley Laboratories, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, United Kingdom., Guzman ML; Department of Hematology & Medical Oncology, Graduate School of Medical Sciences, Cornell University, New York, NY, United States., Wheadon H; Paul O'Gorman Leukaemia Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom., Williams MTS; Charles Oakley Laboratories, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, United Kingdom.

Publikováno v: Frontiers in cell and developmental biology [Front Cell Dev Biol] 2021 Jun 24; Vol. 9, pp. 692800. Date of Electronic Publication: 2021 Jun 24 (Print Publication: 2021).